Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW
February 24, 2015
-
BUSINESS Sun Pharma Wins Japan Approval for Cravit Generics, Competition with Daiichi Sankyo Might Arise
February 23, 2015
-
REGULATORY Gilead’s Sofosbuvir Could Join NHI Price List in May If OK’ed by PAFSC Panel on March 5
February 20, 2015
-
REGULATORY Chuikyo Approves 26 Products Including Takecab, Zelboraf for Listing
February 19, 2015
-
BUSINESS Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief
February 18, 2015
-
REGULATORY Abe Calls for Shrewd Strategies for Pharmas, Industry Consolidation as Necessary
February 18, 2015
-
BUSINESS Nichi-Iko to Exclusively Market Plavix Authorized Generics
February 17, 2015
-
BUSINESS Otsuka Holdings Weighs Staff Realignment as Abilify Patent Expiry Looms
February 16, 2015
-
BUSINESS GSK Eyes Transfer of Oncology Teams to Novartis from March
February 13, 2015
-
BUSINESS Otsuka Pharma Pres. Iwamoto Dies at 54, Holding Firm CEO to Take Over
February 12, 2015
-
BUSINESS Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
February 12, 2015
-
REGULATORY MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets
February 10, 2015
-
ACADEMIA Keio Researcher to Launch Clinical Trial on Repositioned AD Treatment in April
February 9, 2015
-
ORGANIZATION PhRMA Sets to Make Direct Plea to Finance Minister to Drop Annual Price Cut Plan
February 6, 2015
-
REGULATORY NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General
February 6, 2015
-
BUSINESS Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
-
REGULATORY MHLW Plans Business Suspension Order for Novartis
February 5, 2015
-
REGULATORY R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto
February 4, 2015
-
BUSINESS Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
-
BUSINESS Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…